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Abstract Legionella pneumophila peptidoglycan-associ-
ated lipoprotein (PAL) protein is an extremely conserved
antigen among Legionella species. In this study, rabbit and
rat anti-PAL immunoglobulin G antibodies were produced
by immunization with purified, recombinant PAL (r-PAL)
protein of L. pneumophila serogroup 1 and used as capture
and detection antibodies in the PAL antigen-based enzyme-
linked immunosorbent assay (ELISA) to detect urinary
PAL antigen. Urine samples were obtained from rats
experimentally infected with L. pneumophila serogroup 1.
The PAL antigen was measured in urine samples of 40
infected and 40 uninfected rats. After choosing the cut-off
value of 0.192, the sensitivity and specificity of the PAL
antigen-based ELISA were 87.5 and 97.5 %, respectively.
The results obtained by PAL antigen base ELISA were
compared with those obtained by Biotest. The PAL antigen
was detected efficiently by both of the assays and all of the
control human urine samples were negative by the ELISA
test. The PAL antigen-based ELISA assay was relatively
simple to perform, precise, highly sensitive and specific,
and reproducible. Based on our data the PAL antigen-based
ELISA described here is the first indirect sandwich ELISA
for urinary antigen detection which could easily be applied
for diagnosis of Legionnaires disease.
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Introduction
Legionnaire’s disease (LD), a form of severe pneumonia,
caused by Legionella spp. was originally believed to be an
exotic plague. LD still occurs, both in sporadic and epi-
demic form, sometimes involving many hundreds of vic-
tims and can cause high morbidity and mortality (range
30–50 %) if treated improperly (Edelstein and Cianciotto
2005; Winn et al. 2006). Although Legionella pneumophila
ranked as the third most common etiologic agent for
community-acquired pneumonia, diagnosis of Legionella
pneumonia can be difficult. Failure to diagnose LD is lar-
gely due to an absence of clinical awareness. Clinical
manifestations of the patients and radiographic features are
nonspecific, and it is not possible to clinically distinguish
patients with LD from patients with other types of pneu-
monia (Fang et al. 1990; Edelstein 1993).
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The special laboratory tests available for the diagnosis
of LD consist of detection of organisms in respiratory
secretions by a direct flourescent antibody (DFA) test;
antibody determination in serum samples by indirect
immunofluorescent assay (IFA) test; detection of Legion-
ella DNA in respiratory secretions by polymerase chain
reaction (PCR); culture of clinical specimens such as
blood, sputum, biopsy of tissue etc.; and detection of
Legionella antigen in urine specimens (Waterer et al. 2001;
Forgie and Marrie 2009).
Some problems with many accessible diagnostic tests
for legionellae are: insufficient sensitivity and specificity,
and inability to provides a result in a clinically useful time
period (Fields et al. 2002). While DFA supplies a rapid
method of identifying Legionella spp., immunofluorescent
microscopy is technically very demanding and is very
liable to error if not carried out by experienced personnel
(Waterer et al. 2001; Fields et al. 2002). In the clinical
setting, serology is restricted in its usefulness as a diag-
nostic instrument for legionellosis due to the length of time
required, the need for paired sera, and the difficulty of
getting proper convalescent samples (Stout and Yu 1997).
In genotypic methods, the results of PCR for the diagnosis
of Legionella infections seem very hopeful and show that
this method may be more sensitive than other diagnostic
methods. PCR is costly and there are no FDA (the Food
and Drug Administration) approved reagents. In addition,
PCR is used in few laboratories to diagnose LD (Maiwald
et al. 1998). A main limitation of culture-based methods is
that 25–75 % of patients with Legionella pneumonia do not
expectorate sputum, although culture-based diagnosis
remains the gold standard for diagnosis of legionellosis.
Besides, Legionella organisms grow slowly on culture
media, so laboratories that throw away negative cultures
after 5 days may also miss some Legionella-containing
specimens (Waterer et al. 2001; Fields et al. 2002).
Nearly 80 % of patients with L. pneumophila serogroup
1 (SG1) infection excrete Legionella antigens in their urine
at some stage of their illness (Helbig et al. 2003). The
urinary antigen testing revolutionized the laboratory diag-
nosis of LD, making it the most common laboratory test
ordered for diagnosis of such a disease, since this test can
be easily done by those without specific skills. Urine
antigen testing allows primitive diagnosis and beginning of
suitable antibiotic therapy (Kashuba and Ballow 1996;
Edelstein and Cianciotto 2005). Three commercial enzyme
immunoassay (EIA) kits have been reported to be sensitive
and specific in many clinical studies. However, several
authors mentioned that the available commercial EIA kits
revealed excellent sensitivity to L. pneumophila SG1
antigen, but they had changable sensitivity to L. pneumo-
phila non-SG1 and other Legionella species (Dominguez
et al. 2001; Fields et al. 2002; Kim et al. 2003). Although
the L. pneumophila SG1 was the cause of 70–90 % of all
cases of LD in most geographic areas, other L. pneumo-
phila serogroups and other Legionella spp. are being
identified with increment of frequency, therefore ques-
tioning the broad-spectrum utility of these tests (Reingold
et al. 1984; Yu et al. 2002). It is still necessary to develop
antigen capture assays to diagnose infections with all
species and serogroups of Legionella. Expansion of a
genus-wide urinary antigen test looks practicable and
would provide a distinct diagnostic advantage (Harrison
2005). In addition, if a Legionella species-common, surface
antigen is targeted, the value of urinary antigen detection
assays will be significantly increased to diagnose Legion-
ella pneumonia which results from all Legionella species
(Tang and Toma 1986; Kim et al. 2003). Among the
L. pneumophila SG1 antigens, the peptidoglycan-associ-
ated lipoprotein (PAL) of L. pneumophila, as an extremely
conserved portion between all Legionella species, was
identified as the most eminent surface antigen. In addition,
this antigen is a strong antibody inducer in rabbits and
mice, also since it is excreted in infected urine specimens;
it will be diagnostically useful to design an ELISA kit to
diagnose LD (Yoon et al. 2002; Kim et al. 2003).
This paper delineates the development of an indirect
sandwich ELISA for the detection of the PAL antigen from
rats which were infected with L. pneumophila. It demon-
strated that the Legionella PAL antigen was detected effi-
ciently by the PAL antigen-based ELISA.
Materials and methods
Periplasmic expression and purification of r-PAL
protein
Recombinant PAL (r-PAL) protein was previously
expressed and purified by Gholipour et al. (2010, 2012).
Briefly, Luria–Bertani (LB) broth medium (Himedia),
supplemented with kanamycin, (LBB-K) was inoculated
with E. coli BL21 (DE3) carrying the recombinant
pET26b-pal plasmid and the r-PAL protein expression was
induced by adding 1 mM Isopropyl-b-Dthiogalactopyr-
anoside (IPTG). To prepare the periplasmic extract, the
bacterial cells were harvested by centrifugation and the
pellet was re-suspended in TES buffer (0.02 M Tris–Cl,
0.5 M EDTA, and 20 % sucrose, pH = 8.0). Lysozyme
(Boehringer Germany) and complete protease inhibitor
cocktail (Roche) were added to the cell suspension, fol-
lowed by adding ice cold deionized water. The suspension
was agitated on ice and the cells were centrifuged. In order
to purify r-PAL protein, the supernatant was dialyzed
overnight against chromatography buffer, and then the
concentrated dialyzed sample containing r-PAL protein
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added to the Ni–NTA resin, mixed gently and transferred to
the column. The column was washed with chromatography
buffer, the r-PAL protein was eluted and analyzed by SDS-
PAGE and Western blotting.
Rat and rabbit anti-PAL antigen IgG preparation
For acclimatization, two rats and rabbits (New Zealand
White) were held for one week before the beginning of the
procedures. Rats and rabbits back (the sites of injection)
were swabbed down with ethanol cotton balls and sub-
dermal injection was done with 20 and 100 lg of r-PAL
protein, respectively at 2-weeks intervals for 2 months
(Drenckhahn et al. 1993). Hyperimmune sera were col-
lected, and IgG was purified by Protein A antibody puri-
fication kit (Sigma-Aldrich, USA) based on the
manufacturer’s protocol. The purified IgG was identified
by sodium dodecyl sulfate- polyacrylamide gel electro-
phoresis (SDS-PAGE), and the concentration was deter-
mined by Bradford protein assay and finally used for
experiments.
Rat infection and urine sample collection
L. pneumophila SG1 (ATCC33152); obtained from the
American Type Culture Collection (ATCC), Manassas,
VA, was cultured on selective modified Wadowsky-Yee
medium (MWY) (Oxoid) at 37 C and 5 % CO2 under
humidified air for 3–4 days. After incubation, L. pneumo-
phila colonies were harvested to prepare the inoculums for
rat infection.
Intratracheal inoculation of rats were performed with
1 9 106 CFU/animal of L. pneumophila which led to
Legionella pneumonia 48 h after infection (Brieland et al.
1994). Ten male rats (250–350 g) were held for one week
before inoculation. The rats were lightly anesthetized with
ketamine and xylazine, they were tied then a vertical cut
was made through the skin of the ventral neck. Then
200 lL of the bacterial suspension was injected directly
into the trachea with an insulin syringe followed by 200 lL
of air. The skin incision was closed and then the rats were
put to their cages. Ten control rats were also similarly
inoculated with 200 lL of sterile phosphate-buffered saline
(PBS). The rats were watched and controlled for signs of
illness, therefore, urine samples from the infected and
uninfected (control) rats were gained at 3, 6, 9, 15 days
after inoculation and kept in aliquots at -70 C before use
(Kim et al. 2003; Saha et al. 2005). After urine collection,
the rats were gently killed and the lungs were removed,
finely minced in sterile PBS, homogenized and cultured on
MWY agar and incubated at 37 C (5 % CO2 under
humidified air) for 4 days (Brieland et al. 1998).
Chessboard titrations
Many ELISA systems require optimizing the used reagents.
Chessboard titrations (CBTs) are key features to help the
process. (Crowther 2001). We designed indirect sandwich
ELISA based on four parameters for optimization; capture
antibody, antigen, detecting antibody and anti-antibody
conjugated with enzyme. We used L. pneumophila-PAL
recombinant protein which had been optimized and puri-
fied before (Gholipour et al. 2012). Rat anti-PAL IgG was
used as capture and rabbit anti-PAL IgG was used as
detection antibodies. In order to titrate the capture antibody
and antigen (Stage I), the diluent (borate coating buffer)
(pH 9.6) containing boric acid (3.1 g), potassium chloride
(3.5 g), sodium hydroxide (1.3 g) and Phenol red (2 mg)
was added in 50-lL volume to all wells of the micro-
plate (Nunc, Denmark). 50 lL of the capture antibody
(40 lg/ml) was added to all wells in column 1 of the
microplate and it was diluted to column 11. There was no
antibody in column 12 and it only contained borate coating
buffer which it was considered as blank. After incubation at
37 C for 2 h, the microplate was washed three times with
PBS (pH 7.4) and a dilution range of antigen (0.039 to
5 lg/ml) was made from column 1 to column 11 in
blocking buffer (PBS containing 1 % bovine serum albu-
min -BSA, 0.05 % Tween 20). The microplate was incu-
bated at 37 C for 1 h. Then the microplate was washed
and 50 lL of detection antibody (2 lg/ml) was added to
each well. After incubation at 37 C for 2 h, the microplate
was washed and 50 lL of conjugate (1/1,000 in blocking
buffer) was added to each well. Finally after incubation at
37 C for 2 h, the microplate was washed, 50 lL of BM
Blue POD substrate (Rocche, Germany) was added to each
well and microplate was incubated in the dark at room
temperature for 20 min. To stop the color reaction, 50 lL
of stop solution (HCl 2 N) was added to each well and the
optical density (OD) read using a microplate reader (Tecan,
Australia) set to 450 nm. To titration of detection antibody
and conjugate (Stage II), the concentration of capture
antibody and antigen was fixed and the concentration of the
detection antibody and conjugate optimized was the same
as mentioned above.
PAL antigen-based ELISA design
An indirect sandwich ELISA was designed to detect PAL
antigen in urine samples of infected rats, after finding
optimum concentration of capture antibody, antigen,
detection antibody and conjugate from Stage I and II. After
coating the microplate (with optimum concentration of
capture antibody), all urine samples were boiled for 5 min,
centrifuged at 1,2009g for 10 min, and 50 lL of infected
urine specimens, obtained from different days, added to
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duplicate wells. 50 lL of purified r-PAL protein (at opti-
mum concentration found from CBT in Stage I) and 50 lL
of uninfected urine samples were added to copy wells as
positive control and negative controls, respectively. The
next steps of PAL antigen-based ELISA were performed as
described above for CBTs. Human urine samples were
included in this study for cross-reactivity testing.
Biotest Legionella urinary antigen EIA
The Biotest Legionella urinary antigen EIA is a direct
sandwich assay that uses polyclonal rabbit antibodies as the
capture and detection antibodies which react with antigens
of L. pneumophila serogroups, as well as with antigens of
other species of Legionella. The test was performed
according to the manufacturer’s instructions.
Statistical analysis
For antigen determination, all specimens were examined in
duplicate and the results were expressed as the mean
absorbance for each determination. The mean optical
density of the negative samples plus 2* standard deviations
(SDs) was used to calculate cut-off value. The Biotest
Legionella urinary antigen EIA results used as the standard
test. The results were compared by Pearson correlation
analysis which were achieved by the Biotest Legionella
urinary antigen EIA and the PAL antigen-based ELISA.
For sensitivity and specificity value calculations of the
PAL antigen-based ELISA a total of 40 negative urine
samples were collected from uninfected rats and the sen-
sitivity and specificity values were calculated by using each
cut-off value. All statistical analyses were performed by
using the SPSS version 15 for Windows and Microsoft
Excel 2003 software.
Results
Protein A antibody purification kit was used to purify anti-
PAL antigen IgG from serum sample of immunized ani-
mals. The concentration of purified IgG was 1,000 lg/ml.
To confirm specificity of the purified IgG, Western blot
analysis was done by using the purified IgG as an initial
antibody and anti-Rabbit IgG (whole molecule) peroxidase
conjugate (Sigma, A 9169) as a secondary antibody. The
blotted r-PAL protein showed specific signal detection as
well as using anti-His6 peroxidase antibodies.
Recovery of L. pneumophila from infected rats
The lung tissue homogenates of infected rats were cultured
on MWY agar and L. pneumophila colonies observed after
4 days of incubation at 37 C in a humidified 5 % CO2.
This finding confirmed that all rats were infected with
L. pneumophila.
Titration of capture antibody and antigen with constant
detection antibody and conjugate
Two experimental combinations were examined. In the first
one rabbit anti r-PAL IgG was used as capture and
detecting antibody that provided very high optical densities
(0.18–3.87) (Fig. 1) when r-PAL antigen was applied. In
the second combination rat anti r-PAL IgG was used as the
capture antibody and rabbit anti r-PAL IgG as the detecting
antibody that yielded lower optical densities (0.05–1.56)
(Fig. 2) which it was suitable for PAL antigen-based
ELISA. The variation in the capture antibody and antigen
concentration was assessed in multiple assays. The results
confirmed that a 2.5 lg/ml capture antibody (rat anti
r-PAL IgG) concentration and a 0.625 lg/ml r-PAL anti-
gen concentration both had better results. Accordingly,
these concentrations of capture antibody and r-PAL antigen
were applied for later assays.
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Fig. 1 Determination of optimal amounts of capture antibody (rabbit
anti r-PAL IgG) and antigen for PAL antigen-based ELISA. Each line
represented titration of the same dilution range of antigen using a
different concentration of capture antibody. The detection antibody
and conjugate dilution was constant
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Fig. 2 Determination of optimal amounts of capture antibody (rat
anti r-PAL IgG) and antigen for PAL antigen-based ELISA. Each line
represented titration of the same dilution range of antigen using a
different concentration of capture antibody. The detection antibody
and conjugate dilution was constant
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Titration of detection antibody and conjugate
with constant capture antibody and antigen
To determine the optimal concentration of the detection
antibody and conjugate using wells coated with 2.5 lg/ml
capture antibody and also using a 0.625 lg/ml antigen
another chessboard assay was performed. By using the
above concentrations, the optimal values for detection
antibody and conjugate were determined at 1.25 lg/ml and
1/8,000, respectively (Fig. 3).
PAL antigen-based ELISA
The results of the CBT proposed that a 2.5 lg/ml concen-
tration of capture antibody, a 0.625 lg/ml concentration of
r-PAL antigen, a 1.25 lg/ml concentration of detection
antibody and a 1/8,000 dilution of conjugate were suitable
for use in the diagnostic assay. Rat anti-PAL IgG was rec-
ognized as a satisfactory capture antibody since it was
capable to capture the respective antigen with a range of
0.078–5 lg/ml; therefore, the limit of detection was deter-
mined to be approximately 78 ng of r-PAL antigen/ml. To
recognize whether the PAL antigen was excreted in infected
urine specimens or not, the PAL antigen capture ELISA was
performed in duplicates on 40 urine samples obtained from
infected rats—after finding optimum concentration of cap-
ture antibody, detection antibody, and conjugate. The
purified r-PAL protein and urine samples from rats which
were injected with sterile PBS were employed as positive
control and negative controls, respectively.
Biotest Legionella urinary antigen EIA
The experiment was done in duplicates on 40 urine samples
from infected rats and 40 urine samples from rats which
were injected with sterile PBS based on the producer’s
instructions. The cut-off value was computed as the mean
optical density of the negative controls plus 0.200. Urine
samples including PAL antigen with an extinction value
equal to or greater than the cut-off value were regarded
positive.
Calculation of cut-off values, sensitivity and specificity
The negative and positive urine samples were tested by
both PAL antigen-based ELISA and Biotest Legionella
urinary antigen EIA. The cut-off values calculated for
mean ? SD and mean ? 2*SD and to establish the sen-
sitivity, specificity and cut-off value, the urine samples got
from the uninfected control rats were used as negative
samples. PAL antigen-based ELISA OD readings from
samples of these rats ranged from 0.065 to 0.356
(Mean = 0.098, SD = 0.047). The OD for positive urine
samples from infected rats were between 0.148 and 0.937
(Mean = 0.677, SD = 0.21).
The results obtained were compared with those from the
Biotest Legionella urinary antigen EIA to settle the eval-
uation of the PAL antigen-based ELISA as a diagnostic
assay. Figure 4 shows the correlation of the absorbance
values of both antigen assays. The correlation coefficient
was 0.72 (P \ 0.001). In line with the results from the
Biotest Legionella urinary antigen EIA, as a standard, the
PAL antigen-based ELISA PAL antigen was detected
efficiently by both of the assays.
The accomplishment of the PAL antigen-based ELISA
was assessed on both 40 infected urine samples and 40
controls obtained from the uninfected rats. When a cut-off
value of 0.145 was chosen, all 40 infected urine samples were
positive within the absorbance range between 0.148 and
0.937 and 3 out of 40 controls were also positive (sensitivity,
100 %; specificity, 92.5 %). When the cut-off value of 0.192
was chosen, 35 out of 40 infected urine samples were positive
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Fig. 3 Determination of optimal amounts of detection antibody and
conjugate for PAL antigen-based ELISA. Each line represented
titration of the same dilution range of conjugate using a different
concentration of detection antibody. The capture antibody and antigen
dilution was constant PAL
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Fig. 4 Correlation between the absorbance values of the Biotest
Legionella urinary antigen EIA and the PAL antigen-based ELISA.
The Pearson correlation coefficient was 0.72 (P \ 0.001). circle L.
pneumophila
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and 1 out of 40 controls were also positive (sensitivity,
87.5 %; specificity, 97.5 %) (Table 1).
The fulfillment of the Biotest Legionella urinary antigen
EIA was also evaluated on 40 infected urine samples and
40 controls got from the uninfected rats. The cut-off value
was 0.289 and all 40 infected urine samples were positive
within the absorbance range from 0.407 to 0.854
(Mean = 0.675, SD = 0.117) and all 40 controls were
negative within the absorbance range between 0.073 and
0.095 (Mean = 0.089, SD = 0.01) (sensitivity, 100.0 %;
specificity, 100 %). (Table 2).
The PAL antigen-based ELISA was also evaluated for
cross-reactivity. A total of 40 human urine samples were
included in the experiment: 30 urine samples were col-
lected from patients who had urinary tract infection due to
E. coli and Klebsiella pneumoniae and 10 samples from
healthy adults. All of these control samples were negative
by the PAL antigen-based ELISA (Table 3).
Discussion
Legionnaire’s disease (LD) is a prevailing type of serious
pneumonia, but these infections are rarely diagnosed. The
clinical symptoms of infection with Legionella are indis-
tinguishable from the symptoms of other causes of pneu-
monia. Besides, Legionella, the bacteria that cause this
disease, are fastidious and not easily cultured (Bartlett
1993; Fields et al. 2002). To recognize Legionella and to
supply timely and suitable therapy, correct diagnostic
methods are required. Specialized laboratory tests must be
conducted to improve diagnosis, by the clinical microbi-
ology laboratory, on patients in a high-risk category
(Bartram et al. 2007).
Among the particular laboratory tests at hand for the
diagnosis of LD, tests proposed by the Panel are culture on
selective media, which identifies all Legionella strains but
is technically hard and a urine antigen assay for L. pneu-
mophila SG1, a test that is technically not difficult and
trustingly and quickly diagnoses up to 70 % of cases of LD
(Bartlett et al. 1998).
The necessity of alternative diagnostic test to culture for
LD diagnosis is based on urinary antigen detection. Urine
antigen testing is very useful, particularly for patients who
do not produce sufficient sputum for culture (Winn et al.
2006). Urine antigen tests have been represented to be
sensitive (70–100 %) and specific (approaching 100 %) for
detecting L. pneumophila SG1 (Murdoch 2003); other
feasible benefits of the tests are the technical ease of car-
rying out of them and the validity of results after several
days of effective antibiotic treatment (Bartlett et al. 1998).
Notwithstanding the accessibility of immunological and
molecular genetic methods, detection of LD is usually
efficacious only for L. pneumophila SG1 and the sensitivity
and specificity of methods for diagnosing other L. pneu-
mophila serogroups and species of Legionella are far from
perfect (Tartakovskii 2001). At present, accessible kits are
shown to be greatly specific and reliable in usual use, but
the major disadvantage of the kits is that they solely detect
the soluble antigen of L. pneumophila SG1 but do not
effectively detect L. pneumophila non-SG 1 and other
Legionella species (Harrison et al. 1998; Benson et al.
2000). The sensitivity may have been affected by strain
differences of LPS because the soluble antigen detected by
these tests is LPS. Furthermore, the Biotest EIA kit pro-
duced to detect all the serogroups of L. pneumophila also
antigens from other Legionella species do not find out non-
pneumophila Legionella strains as efficiently as L. pneu-
mophila SG1. Hence, the value of urinary antigen tests
would be increased if Legionella infections other than L.
pneumophila SG1 infections could also be detected (Do-
minguez et al. 2001).
The characterization of different antigens of L. pneu-
mophila in bacterial cells has been studied by several
research groups. Initial investigations propose that a
Legionella genus common PAL target is detectable in the
urine of experimentally infected guinea-pigs, whereas the
Table 1 Ranges of sensitivity and specificity of the PAL antigen
capture ELISA by each cut-off value
Cut-off % sensitivity % specificity
0.145 100 92.5
0.192 87.5 97.5
The cut-off value was calculated by using the mean absorbance of
negative controls plus SDs
Table 2 Ranges of sensitivity and specificity of the Biotest Legion-
ella urinary antigen EIA by cut-off value
Cut-off % sensitivity % specificity
0.289 100 100
The cut-off value was calculated by using the mean absorbance of
negative controls plus 0.200
Table 3 Ranges of absorbance values in two control groups deter-
mined by the PAL antigen-based ELISA
Group No. of
urine
samples
Absorbance value
Mean ± SD Min Max
Patients with
urinary tract
infection
30 0.0665 ± 0.0091 0.054 0.085
Healthy adults 10 0.070 ± 0.013 0.051 0.088
Min minimum, Max maximum
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successful detection of common protein antigens like major
outer membron protein (MOMP) or macrophage infectivity
potentiator (MIP) in urine has not been reported (Engleberg
et al. 1984; Engleberg et al. 1991; Ludwig et al. 1991;
Yoon et al. 2002; Kim et al. 2003). The periplasmic
expression of PAL protein, as the most important superfi-
cial antigen of L. pneumophila (Engleberg et al. 1991), was
reported (Gholipour et al. 2010), which can be used in
succeeding evaluation of diagnostic studies.
The purpose of the study was to design a Legionella
recombinant PAL antigen-based ELISA kit for detection of
PAL antigen in the urine of infected rats, assessment of the
sensitivity and specificity of the provided Legionella r-PAL
antigen ELISA kit, and comparing the sensitivity and
specificity of this kit with those of the standard commercial
Legionella urinary antigen ELISA kit for detection of LD.
The first step to establish a sandwich ELISA is to access
to enough amounts of capture antibody that is specific for
the antigen you want to assess, in this case r-PAL protein.
On the other hand, the amount of capture antibody coated
on the microplate wells influences the specificity and sen-
sitivity of the assay (Crowther 2001). Hence, the ideal
amounts of anti-PAL IgG for coating were settled and
according to the results got from the CBT, the PAL anti-
gen-based ELISA was planned for detection of L. pneu-
mophila PAL antigen from urine sample.
Lebrun et al. (1983) assessed the detection of L. pneu-
mophila antigen in urine samples by a sandwich ELISA.
They displayed that urinary antigen was present from the
start of the acute phase of the illness. According to forth-
coming and past studies, the most significant characteristic
of urinary antigen assay emerged to be its high specificity
and a moderate-to-high sensitivity for L. pneumophila
infections, ranging from 56 to 99 %. The distinctions in
sensitivities may be expounded by differences in test and
patient features, the serogroup with which the patient was
infected, and if the urine was concentrated before testing. A
main disadvantage with these tests is their incapability to
reliably detect organisms other than L. pneumophila SG1,
and development of a genus-wide urinary antigen would
prepare a clear diagnostic advantage (Birtles et al. 1990;
Murdoch 2003).
For this purpose, the PAL antigen, a Legionella genus
common antigen, was considered to plan the PAL antigen-
based ELISA. Showing the ability of an indirect sandwich
ELISA for the diagnosis of LD was the first published data,
as far as we know. The results showed that PAL antigen
was not detected in uninfected rat’s urine and urine sam-
ples from rats infected with L. pneumophila SG1 got
positive about 3 days after infection and stayed positive for
up to 2 weeks. This is nearly in agreement with the results
reported by Berdal et al. (1979) for detection of L. pneu-
mophila antigen in urine by ELISA.
Sensitivity and specificity values were considered
according to 40 known positive and 40 known negative
samples. The PAL antigen-based ELISA test using the rat
anti-PAL IgG had sensitivity of 100 % and specificity of
92.5 % when a cut-off value of 0.145 was selected and the
test detected antigen in urine from 40/40 experimentally
infected rats. The sensitivity of the test reduced to 87.5 %
and the specificity enhanced to 97.5 % when a cut-off
value of 0.192 was selected and the test detected antigen in
urine from 35/40 experimentally infected rats. No cross-
reactions with other bacteria in urine samples from patients
with urinary tract infections were noticed and from healthy
adults like other authors (Kohler et al. 1981; Tang and
Toma 1986). Comparison between analytical sensitivity of
the PAL antigen-based ELISA and broad-spectrum ELISA
reported by Tang and Toma (1986) displayed that the PAL
antigen-based ELISA was more sensitive than broad-
spectrum ELISA (with a sensitivity of 70 % and a speci-
ficity of nearly 100 %).
Comparison between analytical sensitivity of the PAL
antigen-based ELISA made in our study and sandwich
ELISA reported by Kim et al. (2003) for diagnosis of PAL
antigen from urine sample of infected guinea pigs dis-
played that the PAL antigen-based ELISA was more sen-
sitive than the sandwich ELISA (with a sensitivity of
76.5–88.2 % and a specificity of 95.5–98.5). ELISA which
was recently described for the detection of Legionella PAL
antigen applied a cytoplasmic expressed protein, PAL, as
antigen. A probable disadvantage of the sandwich ELISA
is that cytoplasmic expressed PAL protein may be con-
taminated with bacterial cytoplasmic proteins and may not
lead to appropriate refolding and described undiagnosed
non-pneumophila species of Legionella (Kim et al. 2003).
The Legionella Urine Antigen EIA (Biotest) is planned
to detect legionellae other than L. pneumophila SG1, but it
does so less reliably than it detects L. pneumophila SG1
(Harrison et al. 1998). The disadvantage of the Biotest EIA
exists in its incapability to recognize the special Legionella
species and/or serogroup that causes the infection. Never-
theless, the Biotest EIA is useful instrument for helping
physicians in the diagnosis and treatment of patients with
LD (Dominguez et al. 1998).
The results of testing the 40 infected rat urine samples
with the Biotest EIA represented that all 40 infected urine
samples were positive and all 40 controls were negative
(sensitivity, 100 %; specificity, 100 %). This was in
accordance with the results reported by Kim et al. (2003)
for detection of L. pneumophila antigen in urine of infected
guinea pigs by Biotest EIA. Test specificity is of paramount
importance for an infection with low prevalence, such as
LD. Harrison et al. (1998) showed that the specificity of the
Biotest EIA was excellent at least for patients with lower
respiratory tract infections, with no false-positive results
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being found among the 123 non-LD patients examined
(Harrison et al. 1998). By comparing of the PAL antigen-
based ELISA and the Biotest EIA results, we deduced that
the efficiency of the PAL antigen based-ELISA for PAL
antigen was very good, providing values almost in close
proximity to those got by the Biotest Legionella urinary
antigen EIA.
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